AstraZeneca, BAE, Exmar, Mersen, Zetes: European Equity Preview

The following companies’ shares may have unusual moves in European trading. Stock symbols are in parentheses and prices are from the last close.

The Stoxx Europe 600 Index fell less than 0.1 percent to 251.16. The Stoxx 50 Index lost less than 0.1 percent to 2,447.44. The Euro Stoxx 50 Index (SX5E), a benchmark for nations using the euro, decreased 0.5 percent to 2,616.57.

AstraZeneca Plc (AZN) : The drugmaker failed to win U.S. clearance to sell motavizumab, a new drug intended to succeed the $1 billion-a-year respiratory medicine Synagis, which loses patent protection in five years. The shares rose 0.8 percent to 3,241 pence.

Air Liquide SA (AI) : The world’s biggest producer of industrial gases said it is investing about 60 million euros in new production units in three countries in the Middle East. The shares slid 0.9 percent to 81.67 euros.

BAE Systems Plc (BA/) : Europe’s largest defense company has been awarded a $629 million order under the Navy Pact, according to the Department of Defense. The shares fell 1.2 percent to 296.5 pence.

BP Plc (BP/) : The oil company’s removal of the capping stack and blowout preventer at its Gulf of Mexico well will be delayed for as long as three days because of high seas, National Incident Commander Thad Allen said. The shares fell 1.5 percent to 379.7 pence on Aug. 27.

Camaieu SA (AMA FP): The designer and marketer of women’s clothing said first-half net income rose 4.8 percent to 32.7 million euros. The shares rose 5.7 percent to 158.5 euros.

Entrepose Contraction SA (ENTC FP): The contractor for oil and gas production said first-half net rose 56 percent to 21.2 million euros. The company said the trend for the full-year remains “good,” although adding that decisions on new projects are taking a longer time. The shares advanced 0.4 percent to 75.68 euros.

Exmar NV (EXM) : The operator of the world’s largest fleet of midsize gas tankers said it obtained contracts covering 75 percent of its very large gas carriers and 90 percent of its midsize gas carriers for the remainder of the year. Exmar also posted a first-half net loss of $45.9 million, compared with a preliminary figure of $48.3 million reported July 29. Exmar dropped 1.4 percent to 5.51 euros.

Fluxys SA (FLUX) : The operator of Belgium’s natural gas network reported first-half net income rose 24 percent to 63.4 million euros and said it offered to take a stake of as much as 25 percent in Electricite de France SA’s planned liquefied-natural-gas terminal in Dunkirk. Fluxys retreated 0.2 percent to 2,335 euros.

Ion Beam Applications SA (IBAB) : Europe’s largest maker of proton-therapy equipment said first-half net income fell 24 percent to 2.31 million euros. The company, which is studying strategic options for its pharmaceuticals unit, said it’s still in talks about an offer it received for a 60 percent stake in its in-vitro diagnostics business and that the offer doesn’t meet all of its requirements. Ion Beam gained 0.4 percent to 7.83 euros.

Mersen (MRN) : The world’s biggest maker of brushes for electrical motors, said it remains “wary” about the chances for economic recovery, after first-half profit rose 26 percent, helped by rebounding sales in Asia. The shares rose 3 percent to 28.19 euros.

Sword Group (SWP) : The technology services company said first-half net income rose to 10.7 million euros from 9.4 million euros. The shares declined 1 percent to 25.65 euros.

Zetes Industries SA (ZTS) : The maker of Belgium’s electronic identity cards forecast fiscal year earnings before interest, tax, depreciation, amortization and one-time items will rise to 17 million euros from 13.6 million euros last year. First-half net income fell 23 percent to 2.33 million euros. Zetes declined 0.3 percent to 15.10 euros.

To contact the reporter on this story: Nikolaj Gammeltoft in New York at ngammeltoft@bloomberg.net

To contact the editor responsible for this story: Nick Baker at nbaker7@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.